VIROBAY
Virobay, Inc. operates as an anti-viral drug discovery and development company. It engages in developing, investigating, and creating treatments for hepatitis C, such as protease and polymerase inhibitors. The company was founded in 2006 and is headquartered in Menlo Park, California.
VIROBAY
Social Links:
Industry:
Biotechnology Neuroscience Pharmaceutical
Founded:
2006-01-01
Address:
Menlo Park, California, United States
Country:
United States
Website Url:
http://www.virobayinc.com
Total Employee:
1+
Status:
Closed
Contact:
(650)833-5700
Email Addresses:
[email protected]
Total Funding:
23.77 M USD
Technology used in webpage:
SPF Content Delivery Network IPv6 US Privacy User Signal Mechanism DoubleClick.Net DigiCert SSL Sectigo SSL Sectigo Domain SSL CPanel Smart App Banner
Similar Organizations
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Alta Partners
Alta Partners investment in Series B - Virobay
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Series B - Virobay
Perceptive Advisors
Perceptive Advisors investment in Series B - Virobay
Sutter Hill Ventures
Sutter Hill Ventures investment in Series B - Virobay
Sutter Hill Ventures
Sutter Hill Ventures investment in Venture Round - Virobay
Alta Partners
Alta Partners investment in Venture Round - Virobay
Sutter Hill Ventures
Sutter Hill Ventures investment in Debt Financing - Virobay
Alta Partners
Alta Partners investment in Debt Financing - Virobay
TPG Growth
TPG Growth investment in Debt Financing - Virobay
Official Site Inspections
http://www.virobayinc.com
- Host name: 172.67.177.243
- IP address: 172.67.177.243
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Virobay"
Virobay - Crunchbase Company Profile & Funding
Virobay, Inc. operates as an anti-viral drug discovery and development company. It engages in developing, investigating, and creating treatments for hepatitis C, such as protease and …See details»
Virobay, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Virobay is a company that specializes in creating protease inhibitors to treat various medical conditions such as neuropathic pain, cancer, autoimmune disorders, and liver diseases. They …See details»
Organization | Virobay Inc.
Virobay Inc. Report issue For profit Phase 1 Founded: Menlo Park CA United States (2006)See details»
Virobay Company Profile 2024: Valuation, Funding
Provider of a cysteine cathepsin platform designed to develop and commercialize novel drugs.See details»
Virobay, Inc. Company Profile | Palo Alto, CA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Virobay, Inc. of Palo Alto, CA. Get the latest business insights from Dun & Bradstreet.See details»
Virobay - VentureRadar
Website: http://www.virobayinc.com/ Develops novel drugs using small molecule cysteine proteases inhibitors for conditions such as neuropathic pain, autoimmune diseases, and …See details»
Virobay Inc - Company Profile and News - Bloomberg Markets
Virobay Inc. provides anti-viral drug discovery and development services. The Company offers drugs for the treatment of utoimmune diseases, neuropathic pain, liver diseases,...See details»
Virobay - Products, Competitors, Financials, Employees, …
Virobay's headquarters is located at 1360 Willow Road, Menlo Park. What is Virobay's latest funding round? Virobay's latest funding round is Series B - II. How much did Virobay raise? …See details»
Virobay - Wikipedia
Virobay is an American pharmaceutical company which develops drugs using a proprietary cysteine cathepsin platform. [1] ^ a b House, Douglas W. (7 Oct 2014). "Virobay on deck for …See details»
Virobay Inc - LinkedIn
Virobay Inc | 130 followers on LinkedIn. Small molecule drug discovery and development.See details»
Virobay | EquityNet
Virobay, Inc. operates as an anti-viral drug discovery and development company. It engages in developing, investigating, and creating treatments for hepatitis C, such as protease and …See details»
Virobay Company Profile -Sales, Contacts, Competitors – Buzzfile
Virobay is in the Noncommercial Research Organizations industry within the Engineering, Accounting, Research, and Management Services sector and has been in business for …See details»
Virobay, Inc. | Insights
Oct 7, 2014 · Biotechnology companies launched half of the initial public offerings completed by venture capital-backed companies in 2014, but the momentum behind the IPO boom is …See details»
Robert Booth - Crunchbase Person Profile
Robert Booth, PhD, is currently the Chief Executive Officer of Virobay, Inc., a drug discovery and development company. Robert Booth was also the Executive Chairman of Virobay, Inc. from …See details»
Virobay, Inc. (Virobay, Inc.) - 药物管线_专利_临床试验_投融营收_最 …
了解Virobay, Inc. (Virobay, Inc.)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验, 3篇新闻和4篇文献，疾病领域:肿瘤，内分泌与代谢疾病，技术平台:小分子化药，药物:VBY …See details»
Virobay | VentureRadar
Website: http://www.virobayinc.com/ Develops novel drugs using small molecule cysteine proteases inhibitors for conditions such as neuropathic pain, autoimmune diseases, and …See details»
Virobay Appoints Thomas J. Dietz, Ph.D. To The Virobay ... - PR …
Feb 25, 2014 · /PRNewswire/ -- Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cathepsin protease inhibitors for the treatment of neuropathic...See details»
Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891
Mar 18, 2013 · The first Phase 1 trial of VBY-891 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and …See details»
VBY-036 - Drug Targets, Indications, Patents - Synapse - Patsnap
VBY-036: a CTSS inhibitors Drug, Initially developed by Virobay, Inc., Now, its global highest R&D status is Pending, Mechanism: CTSS inhibitors(Cathepsin S inhibitors), Therapeutic Areas: …See details»
Virobay Inc. Initiates a Phase 1 Trial of VBY-036, a ... - BioSpace
May 23, 2013 · Virobay's clinical pipeline currently includes product candidates in dermatological diseases, autoimmune disease, neuropathic pain, and liver fibrosis. For more information, …See details»